Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- CD-20 53 81 82 40 nonglycosylated preB proB IFN? Leu16 Leu-16 Bp35 Bp-35
- Product Overview:
CD20 is a non-glycosylated protein encoded by MS4A1 in humans.{59585} It is composed of four transmembrane domains, a single intracellular loop, and two extracellular loop domains with both the N- and C-termini located in the cytosol. CD20 is a general B cell marker that is expressed from the late pre-B lymphocyte stage but is not expressed by pro-B lymphocytes and is lost in terminally differentiated plasma cells and plasmablasts. It forms supramolecular complexes with CD53, CD81, and CD82, as well as MHCII, CD40, B cell receptors, and C-terminal Src kinase-binding protein (CBP) to contribute to signal transduction. MS4A1 expression is variable in B cell malignancies, with the lowest expression found in patients with chronic lymphocytic leukemia (CLL) and the highest expression found in patients with diffuse large B cell lymphoma (DLBCL) or hairy cell lymphomas. MS4A1 expression is enriched on IFN-?-inducible T-box transcription factor-expressing B cells in blood isolated from patients with multiple sclerosis.{59586} Cayman’s CD20 Chimeric Monoclonal Antibody was produced recombinantly from the original 10F381 antibody sequence and can be used for flow cytometry (FC). The 10F381 antibody was generated by fusing human IgG1? domains to the antigen-binding domain of a mouse anti-CD20 antibody.{65464}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.